Danish Formulation TechnologyCertificate of Analysis
| Accession No. | COA-A26Q2RTX0160 |
| Client | Alpha Nordisk |
| Report Date | 6/9/2026 |
| Product | Retatrutide | Lot | A26Q2RTX0160 |
| Chemical | GLP-1 · GIP · GCG Triple Agonist | Mfg Date | 2026-Q2 |
| Form | Pre-mixed Liquid | Exp Date | EXP 05/28 |
| Dose | 90mg | Purity | 99.7% |
| Formula | C₂₁₃H₃₃₄N₄₈O₆₆ | Net Content | 89.7 mg |
| Mol. Weight | 4,759.2 Da | Appearance | Clear colorless solution |
All chemical analysis performed in accordance with European Pharmacopoeia (Ph. Eur.) reference methods — HPLC-UV (C18, 220 nm) for purity; ESI-MS (≤5 ppm) for identity confirmation
| Test | Method | Specification | Result | Status |
|---|---|---|---|---|
| Appearance | Visual inspection | Clear colorless solution | Conforms | ✓ PASS |
| Identity | ESI-MS (≤5 ppm) | Confirmed [M+H]⁺ = 4760.2 | Confirmed | ✓ PASS |
| Purity | HPLC-UV (C18, 220 nm) | ≥99.0% | 99.7% | ✓ PASS |
| Related substances | HPLC-UV | ≤1.0% total | <0.3% | ✓ PASS |
| Endotoxin | LAL (gel-clot) | <1.0 EU/mg | <0.5 EU/mg | ✓ PASS |
| Water content | Karl Fischer | <8.0% | <5.2% | ✓ PASS |
| Counterion | Ion chromatography | Acetate (TFA-free) | Acetate | ✓ PASS |
| Sterility | USP <71> visual | No visible contamination | Conforms | ✓ PASS |
HPLC-UV Chromatogram (220 nm)
ESI Mass Spectrum
Alpha Nordiskalphanordisk.com/verifyalphanordisk.com/methodology — Analytical methodology standardVerify this certificate at alphanordisk.com/verify/A26Q2RTX0160
A26Q2RTX0160Danish Formulation Technology
This Certificate of Analysis is issued by Alpha Nordisk for research and laboratory use documentation. The peptide described is intended exclusively for research and laboratory use. Not for human consumption, clinical, diagnostic, or therapeutic application. Lot traceability and analytical data are maintained by Alpha Nordisk under Danish Formulation Technology standards.